Overview

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effects of the digibind drug on hemodialysis patients with high blood pressure. Digibind is used to treat toxicity from digoxin and digoxin-like molecules which may contribute to high blood pressure.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute on Aging (NIA)
Collaborator:
University of Toledo Health Science Campus
Treatments:
Bufanolides
Digoxin
Marinobufagenin